IMR Press / FBE / Volume 2 / Issue 3 / DOI: 10.2741/E160

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

A new method of screening human papillomavirus genotypes and clinical validation
Show Less
1 Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing, China
2 Research Center of Science and Technology Application of Genome, City University of Hongkong, Hongkong, China
3 Department of gynaecology and obstetrics, Chinese PLA General Hospital, Beijing, China
4 Beijing Aerospace Central Hospital, Beijing, China
Front. Biosci. (Elite Ed) 2010, 2(3), 1015–1027;
Published: 1 June 2010

Human papillomavirus (HPV) infection is a necessary factor in the development of cervical cancer. A new HPV screening method, "Human Papillomavirus Genotyping (HPG)", was developed to detect 29 HPV genotypes distribution in China. The utility of HPG was compared to Hybrid Capture 2 High-Risk HPV DNA test (HC2), and it was determined that the HPG test had been proven to be a more credible and sensitive screening HPV method than the HC2 test. HPV16, HPV 52, HPV 56, and HPV 58 were the four most common HPV genotypes in women who have suffered chronic cervicitis or abnormal vaginal bleeding in China. HPV 16 (28.57%) and 18 (17.86%) were more likely to infect multiple HPV genotypes than other HPV genotypes. Age group more than 50 years had a higher risk than other age groups.

Back to top